Shared on21 Sep 25
Fair value Increased 1.31%

HCA Healthcare’s consensus price target has risen as analysts factor in positive impacts from newly approved Texas payments and strong margins despite softening volumes, reflecting management’s resilience in adapting to policy challenges, with fair value increasing from $398.57 to $403.81. Analyst Commentary Incorporation of preliminary estimates for newly approved state-directed payments in Texas driving upward revisions in price targets.

Shared on06 Sep 25
Fair value Increased 0.58%

Analysts raised their price target for HCA Healthcare slightly to $398.57, citing sustained margin strength and operational resilience despite sector policy concerns, with HCA expected to outperform peers due to its scale and proactive mitigation efforts. Analyst Commentary HCA’s Q2 results showed margin outperformance despite softer volumes, but analysts caution about future margin pressures from compensation ratios and potential policy-related increases in bad debt.